ArticleGene therapy2000
Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 140 citations in OpenAlex.
- The reduced-charge melittin analogue MelP5 improves the transfection of non-viral DNA nanoparticles.Journal of peptide science : an official publication of the European Peptide Society · 2022Article
- High Throughput and Highly Controllable Methods for In Vitro Intracellular Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2020Review
- LINGO-1 siRNA nanoparticles promote central remyelination in ethidium bromide-induced demyelination in rats.Journal of physiology and biochemistry · 2019Article
- Metabolically stabilized double-stranded mRNA polyplexes.Gene therapy · 2018Article
- Article
- Physical energy for drug delivery; poration, concentration and activation.Advanced drug delivery reviews · 2014Review
- Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.BioMed research international · 2014Article
- Engineering biodegradable and multifunctional peptide-based polymers for gene delivery.Journal of biological engineering · 2013Article
- Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.Gene therapy · 2011Article
- Synthesis and in vitro testing of new potent polyacridine-melittin gene delivery peptides.Bioconjugate chemistry · 2010Article
- Carbohydrate polymers for nonviral nucleic acid delivery.Topics in current chemistry · 2010Review
- Physical approaches for nucleic acid delivery to liver.The AAPS journal · 2008Review
- Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate.Journal of controlled release : official journal of the Controlled Release Society · 2008Article
- Pharmacokinetic considerations regarding non-viral cancer gene therapy.Cancer science · 2008Review
- Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.The Journal of infectious diseases · 2006Article
- Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase.Clinical & experimental metastasis · 2006Article
- Intracellular trafficking of nonviral vectors.Gene therapy · 2005Review
- Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation.Gene therapy · 2005Article
- Polymers for DNA delivery.Molecules (Basel, Switzerland) · 2005Review
- A nonviral carrier for targeted gene delivery to tumor cells.Cancer gene therapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To achieve hepatocyte-targeted in vivo gene expression, a carrier that controls both the tissue and intracellular distribution of DNA was designed and synthesized. A cationic polymer, poly(L-ornithine) (pOrn), was modified first with galactose, then with a fusigenic peptide (mHA2) to obtain Gal-pOrn-mHA2. When applied with Gal-pOrn-mHA2 to asialoglycoprotein receptor-positive cells, fluorescein-labeled DNA showed a diffuse profile, suggesting the release of DNA from endosomes and/or lysosomes by the carrier. Then the biodistribution and gene expression after intravenous injection of DNA complexes (10 microg DNA per mouse) were examined. After injection of [32P]DNA/Gal-pOrn-mHA2, about 60% of the radioactivity was recovered in the liver, mostly in parenchymal cells. A large amount (81 ng/g tissue) of transgene product (luciferase) was detected in the liver of mice injected with DNA/Gal-pOm-mHA2, which was 280-fold greater than that obtained with DNA/DOTMA:Chol liposomes (50 microg DNA). Prior administration of galactosylated albumin reduced the gene expression to 1/100, indicating the asialoglycoprotein receptor-mediated gene transfer in liver parenchymal cells, ie hepatocytes. The luciferase activity in hepatocytes contributed more than 95% of the total activity in all the tissues examined. Thus, hepatocyte-targeted in vivo gene expression was achieved by the intravenous injection of DNA complex with the multifunctional gene carrier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.